11 results
To examine the effect of L-dopa addition to optimal D2-blocking antipsychotic treatment on positive symptoms, negative symptoms, cognitive symptoms and extrapyramidal symptoms in schizophrenia.
Primary Objectives:- To investigate the effects of a single dose (plasma concentration) 5-HTP challenge test (5-HTP200mg/CBD100+50mg/granisetron2mg) on hypothalamic fMRS activation patterns in healthy male volunteers.Secondary Objectives:- To assess…
Primary:1. To establish the effect of MCP on the release of plasma AVP and subsequent ACTH and cortisol secretion in the absence of a 5HTP-challenge.2. To establish the effect of MCP on the release of plasma AVP and subsequent ACTH and cortisol…
To investigate the effects of galantamine on cognitive impairment and visual hallucinations in Parkinson`s disease, both therapeutic (direct effect) and preventive (protection against an acute increase of dopaminergic medication used by the patient…
To replicate and extend the findings of the recent methylphenidate study in which methylphenidate was found to enhance episodic memory performance; To explore whether this effect of methylphenidate is primarily mediated by its dopaminergic action.
Primary Safety Objective: To describe the safety profile of 20vPnC
This is a medical-scientific research study. The purpose of the study is to investigate the effect of multiple doses of the study compound BIA 28-6156 on the pharmacokinetics of the drugs levodopa-carbidopa (Group 1) and levodopa-benserazide (Group…
to assess whether a single-dose of levodopa improves cognitive symptoms and balances goal-directed and habitual behavior.
To assess the safety, tolerability, and efficacy of ABBV-154 administered every other week (eow) and every 4 weeks (e4w) subcutaneously (SC) vs placebo in subjects with moderately to severely active RA with inadequate response to at least one prior…
To assess the safety and efficacy of ABBV-154 versus placebo in subjects with PMR, who are dependent on treatment with glucocorticoids withdoses of at least 5 mg/day prednisone equivalent (glucocorticoindependent PMR).
The primary objective of the study is to assess the efficacy, safety, and tolerability of ABBV 154 in comparison with placebo in subjects with moderately to severely active CD who had inadequate response to or were intolerant of prior biologics.